Bova welcomes Andrew Rowe as Chief Operating Officer to lead global expansion and innovation
5th May 2025
Bova Group, a leading name in veterinary pharmaceutical compounding, is proud to announce the appointment of Andrew Rowe as its new Chief Operating Officer.
In this pivotal role, Andrew will oversee global operations across Bova UK and Bova Aus, guiding strategic growth and enhancing the customer experience for veterinary surgeons worldwide.
About Andrew Rowe
Andrew’s career in pharmaceutical compounding began early, at just 15 years old, developing a deep, lifelong passion for the industry. Over a decade at Medisca, a global leader in compounding supplies, Andrew achieved significant milestones, including launching Medisca Compounding Supplies in Australia, now the country’s largest raw-ingredient supplier, and expanding operations into the UK and Europe. Most recently, Andrew has leveraged his expertise in healthcare consulting, delivering operational and strategic solutions across the sector.
Andrew’s appointment signals a bold new chapter for Bova, with a sharpened focus on research and development and the rapid delivery of innovative solutions for veterinary surgeons.
Andrew’s Vision for Bova
I am thrilled to be joining Bova at such an exciting time,” said Andrew Rowe. “My passion has always been bringing new ideas to life in ways that directly benefit clinicians and their patients. I look forward to working closely with our teams around the world to strengthen operations, accelerate innovation, and set new standards in the veterinary compounding space.
CEO Nick Bova on the Appointment
Nick Bova, Chief Executive Officer of Bova Group, also shared his enthusiasm for the appointment:
Andrew brings a wealth of operational expertise and an exceptional track record of strategic leadership,” said Nick Bova. “His deep industry experience and innovative mindset will allow us to place even greater emphasis on R&D. We are committed to delivering new, cutting-edge solutions to veterinary surgeons, helping them achieve better outcomes and ultimately improve the lives of animals. With Andrew’s leadership and our existing experienced team, I’m confident we will continue to redefine excellence in our industry.
Bova’s Commitment to Innovation and Growth
With Andrew’s vision and leadership, Bova is poised to introduce a new wave of product innovation and service excellence, reaffirming its position as a trusted partner for veterinary professionals worldwide.
About Bova Group
Bova is a global leader in the compounding of veterinary pharmaceuticals, dedicated to innovation, quality, and the advancement of animal health. Through its operations in Australia, the UK, and beyond, Bova supports veterinary professionals with customised solutions and outstanding customer service.
Bova Group is owned by Nextmune, part of the Vimian family.
